Branded

The FDA's approval of Regeneron and Sanofi's Dupixent provides patients with moderate-to-severe asthma, age 12 years old and older, with a new treatment option.

Fresenius Kabi is offering the first FDA-approved prefilled delivery system for palonosetron hydrochloride injection for cancer patients.

The FDA has approved Regeneron’s Libtayo for metastatic cutaneous squamous cell carcinoma, the second-most common cancer in the United States.

The Food and Drug Administration has approved Talzenna and a companion diagnostic, both of which Pfizer will market.

Akcea and Ionis have received FDA approval for Tegsedi, an injection that can be self-administered.

The FDA has approved Janssen's blood thinner Xarelto to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease.

Insmed’s Arikayce has received FDA approval under the limited population pathway for antibacterial and antifungal drugs.

Paratek has received the FDA's nod for Nuzyra for community-acquired bacterial pneumonia and acute skin and skin structure infections, as well as Seysera for acne.